ZYNEX 45% ABOVE ANALYSTS TARGET, UPGRADES OR DOWNGRADES COMING?

Zynex operates through the Electrotherapy and Pain Management Products segment. The company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. - ZMI. Its other subsidiaries include Zynex Monitoring Solutions, Inc. - ZMS and Zynex Europe, ApS - ZEU. ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.

AVERAGE ANALYSTS PRICE TARGET $8.38
AVERAGE ANALYSTS RECOMMENDATION BUY

COMPANY PROFILE
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. Zynex was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.